Selected summaries LA-5 - Probiotik

1 Chr. Hansen A/S -10-12 B ge All DK-2970 H rsholm, Denmark - Phone: +45 45 74 74 74 - Fax: +45 45 74 88 88 - The information contained herein is to the best of our knowledge true and correct and presented in good faith. It may be subject to change without further notice. To the best of our knowledge this product does not infringe Intellectual Property Rights of any third party. This information is offered solely for your consideration and verification. Copyright Chr. Hansen A/S. All rights reserved. This binder provides you with summaries of Selected publications on Lactobacillus acidophilus LA-5.

2 The publications are clinical studies performed in humans documenting the effects in various conditions. October 2011 Chr. Hansen A/S Human Health & Nutrition Study summaries LA-5 Study summaries LA-5 Chr. Hansen A/S -10-12 B ge All DK-2970 H rsholm, Denmark - Phone: +45 45 74 74 74 - Fax: +45 45 74 88 88 - The information contained herein is to the best of our knowledge true and correct and presented in good faith. It may be subject to change without further notice. To the best of our knowledge this product does not infringe Intellectual Property Rights of any third party.

3 This information is offered solely for your consideration and verification. Copyright Chr. Hansen A/S. All rights reserved. Research field: Gastrointestinal Health Research subfield: Diarrhea Study type: Human study Probiotic strain: B. animalis subsp. lactis BB-12 and L. acidophilus LA-5 Dosage CFU/day: 4 billion Product formulation: Capsules Reference number: 1326 Bhalla. Randomized placebo-controlled, double blind, Multicentric Trial on Efficacy and Safety of Providac techsules (Lactobacillus acidophilus LA-5 and Bifidobacterium BB -12) for prevention of Antibiotic-Associated Diarrhea in Indian patients.

4 ACCP 2011;Chicago, Illinois:. Abstract: Statement of Purpose, Innovation or Hypothesis: The role of probiotics in Antibiotic Associated Diarrhoea [AAD] has not been well studied. This trial evaluated the efficacy and safety of Providac techsules in the prevention of AAD in Indian patients. Description of Methods and Materials: Double blind placebo controlled multicentric trial with patients of either gender who require a systemic oral antibiotic therapy for 7 days were randomized into Providac or placebo treatment, taken twice daily after food for 14 days and followed up with symptom diary card for AAD assessment.

5 Data and Results: Evaluable subjects, 176 in the Providac group while 167 in the placebo group, had comparable baseline profiles. After 14 days therapy, incidence of AAD in the Providac group was compared to in the placebo group(p= ). The duration of diarrhoea was significantly less (p= ) in the Providac group ( days ) compared to the placebo ( days) group. Severe diarrhoea - (manifested as watery stool) was more in the Placebo group (96%) than the Providac group ( ) and this difference was highly significant statistically (p< ).

6 There were no Serious Adverse Events in any of the treatment arms and the adverse events which were observed were all non-serious, mild and self limiting. Interpretation, Conclusion or Significance: In Indian adult patients with AAD, Providac can effectively reduce the duration of diarrhea as well as its severity in terms of consistency of stools. ------------------- Study summaries LA-5 Chr. Hansen A/S -10-12 B ge All DK-2970 H rsholm, Denmark - Phone: +45 45 74 74 74 - Fax: +45 45 74 88 88 - The information contained herein is to the best of our knowledge true and correct and presented in good faith.

7 It may be subject to change without further notice. To the best of our knowledge this product does not infringe Intellectual Property Rights of any third party. This information is offered solely for your consideration and verification. Copyright Chr. Hansen A/S. All rights reserved. Research field: Immune Health Research subfield: Inflammation Study type: Human study Probiotic strain: B. animalis subsp. lactis BB-12 and L. acidophilus LA-5 Dosage CFU/day: 2 billion Product formulation: Fermented milk Reference number: 1350 Asemi, et al.

8 Effects of daily consumption of probiotic yoghurt on inflammatory factors in pregnant women: a randomized controlled trial 2011;14(8):476-482 Abstract: Previous studies have shown that inflammatory factors increases in pregnancy and is associated with several complications of pregnancy. The aim of this study was to assess effects of daily consumption of probiotic yoghurt on inflammatory factors in pregnant women. In a randomized clinical trial, seventy primigravid (the first pregnancy) and singleton pregnant women aged 18-30 years were assigned to two groups.

9 Subjects consumed daily 200 g probiotic yoghurt containing Lactobacillus acidophilus La5 and Bifidobacterium animalis BB12 (10(7) CFU g(-1) for each) or 200 g conventional yoghurt for 9 weeks. Fasting blood samples were collected at baseline (28 weeks of gestation) and after intervention (37 weeks of gestation). Inflammatory factors, hs-CRP and TNF-alpha, were measured by Enzyme-linked Immunosorbent Assay (ELISA). Independent t-test was used to compare the two groups after intervention and paired-sample t-test compared variables before and after treatment.

10 The results showed that the probiotic yogurt brought about a decrease in the serum hs-CRP level, from +/- to +/- microg mL(-1) (p = ). There was no significant change in the conventional yogurt group in the serum hs-CRP level ( +/- to +/- microg mL(-1), p = ). The probiotic yogurt had no effect on TNF-alpha (from +/- to +/- pg mL(-1), p = ). Serum TNF-alpha did not change in the conventional yogurt group (p = ). In conclusion probiotic yogurt significantly decreased hs-CRP in pregnant women but had no effect on TNF-alpha.